A novel nomogram predicting lymph node invasion among patients with prostate cancer: The importance of extracapsular extension at multiparametric magnetic resonance imaging.


Journal

Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460

Informations de publication

Date de publication:
07 2021
Historique:
received: 29 07 2020
revised: 24 11 2020
accepted: 29 11 2020
pubmed: 12 1 2021
medline: 24 12 2021
entrez: 11 1 2021
Statut: ppublish

Résumé

To develop a novel risk tool that allows the prediction of lymph node invasion (LNI) among patients with prostate cancer (PCa) treated with robot-assisted radical prostatectomy (RARP) and extended pelvic lymph node dissection (ePLND). We retrospectively identified 742 patients treated with RARP + ePLND at a single center between 2012 and 2018. All patients underwent multiparametric magnetic resonance imaging (mpMRI) and were diagnosed with targeted biopsies. First, the nomogram published by Briganti et al. was validated in our cohort. Second, three novel multivariable logistic regression models predicting LNI were developed: (1) a complete model fitted with PSA, ISUP grade groups, percentage of positive cores (PCP), extracapsular extension (ECE), and Prostate Imaging Reporting and Data System (PI-RADS) score; (2) a simplified model where ECE score was not included (model 1); and (3) a simplified model where PI-RADS score was not included (model 2). The predictive accuracy of the models was assessed with the receiver operating characteristic-derived area under the curve (AUC). Calibration plots and decision curve analyses were used. Overall, 149 patients (20%) had LNI. In multivariable logistic regression models, PSA (OR: 1.03; P= 0.001), ISUP grade groups (OR: 1.33; P= 0.001), PCP (OR: 1.01; P= 0.01), and ECE score (ECE 4 vs. 3 OR: 2.99; ECE 5 vs. 3 OR: 6.97; P< 0.001) were associated with higher rates of LNI. The AUC of the Briganti et al. model was 74%. Conversely, the AUC of model 1 vs. model 2 vs. complete model was, respectively, 78% vs. 81% vs. 81%. Simplified model 1 (ECE score only) was then chosen as the best performing model. A nomogram to calculate the individual probability of LNI, based on model 1 was created. Setting our cut-off at 5% we missed only 2.6% of LNI patients. We developed a novel nomogram that combines PSA, ISUP grade groups, PCP, and mpMRI-derived ECE score to predict the probability of LNI at final pathology in RARP candidates. The application of a nomogram derived cut-off of 5% allows to avoid a consistent number of ePLND procedures, missing only 2.6% of LNI patients. External validation of our model is needed.

Identifiants

pubmed: 33423938
pii: S1078-1439(20)30626-8
doi: 10.1016/j.urolonc.2020.11.040
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

431.e15-431.e22

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

E Di Trapani (E)

Division of Urology, IEO - European Institute of Oncology, IRCCS, Milan, Italy. Electronic address: ettore.ditrapani@ieo.it.

S Luzzago (S)

Division of Urology, IEO - European Institute of Oncology, IRCCS, Milan, Italy.

G Peveri (G)

Department of Molecular and Translational Medicine, Università degli Studi di Brescia, Brescia, Italy.

M Catellani (M)

Division of Urology, IEO - European Institute of Oncology, IRCCS, Milan, Italy.

M Ferro (M)

Division of Urology, IEO - European Institute of Oncology, IRCCS, Milan, Italy.

G Cordima (G)

Division of Urology, IEO - European Institute of Oncology, IRCCS, Milan, Italy.

F A Mistretta (FA)

Division of Urology, IEO - European Institute of Oncology, IRCCS, Milan, Italy.

R Bianchi (R)

Division of Urology, IEO - European Institute of Oncology, IRCCS, Milan, Italy.

G Cozzi (G)

Division of Urology, IEO - European Institute of Oncology, IRCCS, Milan, Italy.

S Alessi (S)

Division of Precision Imaging and Radiation Sciences, IEO - European Institute of Oncology, IRCCS, Milan, Italy.

D V Matei (DV)

Division of Urology, IEO - European Institute of Oncology, IRCCS, Milan, Italy.

V Bagnardi (V)

Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy.

G Petralia (G)

Division of Precision Imaging and Radiation Sciences, IEO - European Institute of Oncology, IRCCS, Milan, Italy.

G Musi (G)

Division of Urology, IEO - European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hematology-Oncology, Università degli Studi di Milano, Milan, Italy.

O De Cobelli (O)

Division of Urology, IEO - European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hematology-Oncology, Università degli Studi di Milano, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH